[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402489":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":51,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":55,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Institut Paoli-Calmettes","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RFA treatment efficacy","EXPERIMENTAL","PNETs ablation by radiofrequency treatment (1 to 3 sessions)",[13],"Procedure: Radiofrequency ablation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Radiofrequency ablation","RFA is performed under general anaesthesia, under high endoscopic echo-endoscopy (EEH), in left lateral decubitus position, using the StarMed generator from Taewong®.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Fabrice CAILLOL, MD","Paoli Calmettes Institute","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Jihane PAKRADOUNI","CONTACT","+33491223778","drci.up@ipc.unicancer.fr",[33],{"facility":34,"status":35,"city":36,"state":20,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Institut Paoli Calmettes","RECRUITING","Marseille","13009","France","FR",{"type":41,"coordinates":42},"Point",[43,44],5.38107,43.29695,{"lat":44,"lon":43},[47,49],{"name":28,"role":29,"phone":48,"phoneExt":20,"email":31},"+ 33 4 91 22 37 78",{"name":50,"role":29,"phone":48,"phoneExt":20,"email":31},"Delphine MARIE",{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100402489","pancreatic-radiofrequency-under-high-echo-endoscopy-in-the-management-of-pancreatic-neuroendocrine-tumors-100402489",false,"NCT04520932","Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Pancreatic Neuroendocrine Tumors","Pancreatic Radiofrequency Under High Echo-endoscopy in the Management of Low Grade Pancreatic Neuroendocrine Tumors of Less Than 2cm in Size","RFANET","Inclusion Criteria:\n\n* Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;\n* Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67\\\u003C3%,\n* Non-secretory lesion.\n* Homogeneous HEE contrast taking;\n* No positron emission tomography (PET) FDG binding to the pancreatic mass;\n* Lesion \\\u003C20mm on conventional imaging at 6 months monitoring;\n* Age 18 to 80 years inclusive;\n* Patient in good general condition, World Health Organization \\[0-1\\];\n* Signed consent to participate;\n* Affiliation to healthcare insurance system or beneficiary of this regimen.\n\nExclusion Criteria:\n\n* Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;\n* A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.\n* Life expectancy \\\u003C 1 year;\n* Severe hemostasis disorders;\n* Pancreatic and\u002For biliary ductal dilation;\n* Lesion considered to be adjacent to the pancreatic duct and\u002For bile duct;\n* Node extension and\u002For metastatic disease;\n* Patient being managed for another malignant lesion which is progressive or under treatment.","ALL","18 Years","80 Years",{"count":65,"type":66},82,"ESTIMATED","INTERVENTIONAL",[69],"NA","Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.",[72,73],"Neuroendocrine Tumor of Pancreas (Disorder)","Neuroendocrine Tumor Grade 1",[75,76,77,78],"Radio Frequency treatment","Echoendoscopy","Ablation","Efficacy","2025-05-23",{"date":81,"type":82},"2025-05-25","ACTUAL",{"date":84,"type":82},"2021-03-30",{"date":86,"type":66},"2031-04",{"name":5,"class":6},1]